Denna sida på svenska

Sebastian Lewandowski

Laboratory engineer

About me

We study neurodegeneration and dementia in ALS, FTD and AD to find novel therapeutic applications and biomarkers of vascular injury.

We look how blood-brain barrier dysfunction and vascular remodeling leads to increased severity of stroke, Amyotrophic Lateral Sclerosis (ALS) and FTD using bioinformatics, in-vivo rodent models and clinical samples. We collaborate with the leading neurology centers in Europe and US including UZ Leuven in Belgium, Univ. Utrecht in Holland, Ulm Univ. in Germany and UCSD in San Diego. Our results lead to novel off-label drug applications to therapy and biomarkers in neurodegeneration including ALS, stroke and Multiple Sclerosis.

Methods: Single cell transcriptome analysis, Cell-type specific expression enrichment, Expression network analysis, Histology, Immunostainings, Immunobead plasma proteomics.

Collaborations with clinical and research groups:
- VIB-KU Leuven Center for Brain & Disease Research, Belgium. Prof. Philip van Damme
- UMC Utrecht Brain Center, Netherlands. Prof. Jan Veldink
- Neurology Dept. University Ulm, Germany. Prof. Albert Ludolph
- Neurosciences Dept. University of California, San Diego, US. Prof. John Ravits
- SciLifeLab, School of Biotechnology, KTH, Sweden. Prof. Peter Nilsson
- Neurosciences Dept. Karolinska Institute., Sweden. Prof. Eva Hedlund

Education

2005 – PhD degree in Molecular Biology
Nencki Institute of Experimental Biology, Warsaw, Poland

1997 – MSc degree in Biophysics.

Molecular Biology at University of Gdansk, Poland

Teaching portfolio

- Completed courses in teaching:

(2013) Full time course on teaching at KI (Course leader: Maria Weurlander)

- Different types of teaching assignments:

Group discussions (2009-2017), Seminars (2010-2017), Laboratory work (2012-2013), Lecturer (2012-2017), PhD course director (2014)

-Planned, developed and led a new postgraduate course:

Course director (PhD Level) DBRM3: Neurovascular Regenerative Medicine, From Development to Disease - (2014).

- Student supervision. Summer Research School. Dept. of Biosciences and Nutrition. Ksenia Belobordova. Direct supervision in science project concluded in a written and oral report. Summer 2006

Publications

Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders
Lewandowski Sa, Fredriksson L, Lawrence Da, Eriksson U
Pharmacology & therapeutics 2016;167():108-119

Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration
Lewandowski Sa, Nilsson I, Fredriksson L, Lönnerberg P, Muhl L, Zeitelhofer M, et al
Acta neuropathologica 2016;131(3):453-64

Response to the report, "A re-assessment of treatment with a tyrosine kinase inhibitor (imatinib) on tissue sparing and functional recovery after spinal cord injury" by Sharp et al
Abrams Mb, Nilsson I, Kjell J, Lewandowski S, Codeluppi S, Eriksson U, et al
Experimental neurology 2014;257():182-5

Imatinib enhances functional outcome after spinal cord injury
Abrams Mb, Nilsson I, Lewandowski Sa, Kjell J, Codeluppi S, Olson L, et al
PloS one 2012;7(6):e38760-

The oxysterol receptor LXR inhibits proliferation of human breast cancer cells
Vedin Ll, Lewandowski Sa, Parini P, Gustafsson Ja, Steffensen Kr
Carcinogenesis 2009;30(4):575-9

A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells
Williams C, Edvardsson K, Lewandowski Sa, Ström A, Gustafsson Ja
Oncogene 2008;27(7):1019-32

Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity
Lewandowski Sa, Thiery J, Jalil A, Leclercq G, Szczylik C, Chouaib S
ONCOGENE 2005;24(30):4789-98

Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium
Skrzypczak M, Bieche I, Szymczak S, Tozlu S, Lewandowski S, Girault I, et al
International journal of cancer 2004;110(6):783-7

Estrogen receptor beta - Potential functional significance of a variety of mRNA isoforms
Lewandowski S, Kalita K, Kaczmarek L
FEBS LETTERS 2002;524(1-3):1-5

Antitumor activity of tributyrin in murine melanoma model
Giermasz A, Nowis D, Jalili A, Basak G, Marczak M, Makowski M, et al
Cancer letters 2001;164(2):143-8

Map

Videos

Our 2014 ALS Ice Bucket Challenge:

 

Blood-brain barrier dysfunction in ALS

 

In the News:

http://www.fondation-thierry-latran.org/english/new-insight-into-als-disease-origins-leads-to-targeted-novel-therapies/